Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations

Research output: Contribution to journalArticle


Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed. Treatment selection generally depends on patient need, age and fitness, time of relapse, and line of therapy. Combination regimens typically produce higher response rates than single agents, and adding rituximab generally improves outcomes. The inclusion of ibrutinib, lenalidomide, temsirolimus, and bortezomib, represents an important advance for patients ineligible for, unable to tolerate, or failing high-intensity combination chemotherapy. A high need for effective treatments in relapsed/refractory MCL remains, particularly for elderly and frail patients.


  • Martin Dreyling
  • Igor Aurer
  • Sergio Cortelazzo
  • Olivier Hermine
  • Georg Hess
  • Mats Jerkeman
  • Steven Le Gouill
  • Vincent Ribrag
  • Marek Trněný
  • Carlo Visco
  • Jan Walewski
  • Francesco Zaja
  • Pier Luigi Zinzani
External organisations
  • Paris Descartes University
  • University of Mainz
  • Nantes University Hospital
  • Institut Gustave Roussy
  • Charles University in Prague
  • Ospedale San Bortolo
  • The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
  • Ludwig-Maximilian University of Munich
  • University Hospital Centre Zagreb
  • Humanitas Gavazzeni - Ospedale a Bergamo
  • University of Udine
  • University of Bologna
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology


  • Chemotherapy, clinical trials, mantle cell lymphoma, molecular targeted therapy
Original languageEnglish
Pages (from-to)1814-1828
JournalLeukemia and Lymphoma
Issue number8
Early online date2017 Nov 27
Publication statusPublished - 2018
Publication categoryResearch